A recent phase 2 clinical trial in T2DM patients reported that under euglycaemic hyperinsulinaemic conditions, metformin increased 18F-DG uptake in the small intestine and colon in an insulin independent manner, and colonic glucose uptake was positively correlated with reduced fasting plasma levels in the metformin cohorts24. This evidence concerns the gene INS and type 2 diabetes mellitus.